Last week we noted that adding MRI data to the Partin tables and to the Kattan/MSKCC nomograms did not seem to improve the accuracy of prognosis of outcomes after radical prostatectomy. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: biopsy, clinically significant, data, Gleason 7, MRI, outcome, PI-RADS, prediction, PSA, risk | 5 Comments »
Not so long ago, one of the new immunotherapeutic agents (a PD-1 inhibitor called pembrolizumab or Keytruda) was approved by the US Food and Drug Administration (FDA) for the treatment of so-called microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors — regardless of the biological site of origin of those tumors. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: dMMR, genotype, Management, MSI-H, phenotype, prevalence, rare, risk | 1 Comment »
An obvious but previously unanswered question has been whether adding data from the results of MRI scans to the data used in the Partin tables and in the pre-surgical Kattan nomogram (also known as the Memorial-Sloan Kettering Cancer Center or MSKCC nomogram) can improve the accuracy of these two commonly used prognostic methods. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Kattan, MRI. mpMRI, MSKCC, multiparametric, nomogram, Partin, prognosis, risk, score | 3 Comments »
For many years now, there have been subsets of specialists and patients who have argued that the “standard” serum testosterone level of 50 ng/dl, used by regulatory authorities and others as a measure indicating a castrate level of serum testosterone, is too high. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castrate, dhydrotestosterone, estosterone, level, serum | 18 Comments »
A newly published study in Urologic Oncology has reported data from a survey carried out by researchers at the National Cancer Institute into “the current practice patterns and views among urologists regarding focal therapy for prostate cancer”. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: attitude, belief, focal, therapy, use | 2 Comments »
Pfizer and Astellas have, this morning, announced that the addition of enzalutamide to standard androgen deprivation (ADT) has led to improved outcomes in men with metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, ARCHES, deprivation, enzalutamide, hormone, outcome, sensitive, standard, trial | 2 Comments »
